USA flag logo/image

An Official Website of the United States Government

Targeted Antimicrobial Therapy for Dental Caries

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75574
Program Year/Program:
2005 / STTR
Agency Tracking Number:
MD001831
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
C3 JIAN, INC.
C3 JIAN, INC. 872 3-CRABS RD SEQUIM, WA 98382
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Targeted Antimicrobial Therapy for Dental Caries
Agency: HHS
Contract: 1R41MD001831-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Dental caries (tooth decay) is one of the most prevalent and costly infectious diseases in the United States affecting approximately 52% of children aged 5 to 9 years and approximately 85% adults 18 or older. Currently, the annual expenditures on dental services in the United States exceed $70 billion with the majority of these costs attributable to dental caries. Extensive research has demonstrated that dental caries is caused by the overgrowth of a group of cariogenic bacteria (i.e. Streptococcus mutans) that co-reside with over 400 other non-harmful/commensal microbial species in the dental plaque. The current anti-microbial strategies used to treat dental caries are not effective due to the nonspecific nature of these therapies. In this study, we propose a novel approach to selectively kill or inhibit the cariogenic bacteria within a dental plaque, thus achieving long-lasting therapeutic effects. We propose to use the "smart-bomb" technology to develop antimicrobial peptides specifically targeting S. mutans. In phase 1, we will identify the targeting peptides, construct target specific antimicrobial peptides, and test their efficacy with our well developed in vitro dental plaque systems. More specifically, the phase 1 goals are: 1. To obtain peptides that bind specifically to S. mutans. These peptides will be identified through 1) examining the known S. mutans-binding peptides such as CSP (competence stimulating peptide), 2) isolating small peptides produced and secreted by the cell cultures of S. mutans, 3) chemically synthesizing and testing small peptides identified through mining the S. mutans genome sequence. 2. To construct anti-S. mutans peptides by fusing the above targeting peptides with an antimicrobial defensin peptide (i.e. novispirin G10). The resulting fusion peptides will be tested for their ability to selectively kill S. mutans in liquid cultures or within multi species in vitro dental biofilms.

Principal Investigator:

Maxwell H. Anderson
3606815033
maxscruiser@gmail.com

Business Contact:


2065287309
Small Business Information at Submission:

C-Three Scientific Corporation
C-Three Scientific Corporation 9706 4Th Ave Ne Seattle, WA 98115

EIN/Tax ID: 505509137
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UCLA
UNIVERSITY OF CALIFORNIA LOS ANGELES
Office of Research Administration
LOS ANGELES, CA 90024
RI Type: Nonprofit college or university